PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

PTC Therapeutics (PTCT) Misses Q4 EPS by 14c, Revenues Beat

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.08), $0.14 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $118.86 million versus the consensus estimate of $111.36 million.

"Despite the challenges of the pandemic, PTC has been able to make significant... More